Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET
Company Participants
Henry Wheeler - VP, IR and Communication
Mondher Mahjoubi - CEO
Sonia Quaratino - Chief Medical Officer
Yannis Morel - EVP, BD and Product Portfolio Strategy
Conference Call Participants
Rabib Chaudhury - Leerink Partners
Carly Kenselaar - Citi
Arthur He - H.C. Wainwright
Jingming Chen - Evercore ISI
Operator
Thank you for standing by, and welcome to the Innate Pharma Third Quarter 2023 Financial Results and Business Update.
I would now like to welcome Henry Wheeler, VP, Investor Relations and Communications, to begin the call. Henry, over to you.
Henry Wheeler
Thank you very much. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release for our Q3 financial results and business updates. We look forward to highlighting the progress made during the year-to-date as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.
On Slide 2, before we start, I'd like to remind you that we will be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted
On Slide 3, on today's call, we will be joined by Mondher Mahjoubi, our Chief Executive Officer. Then we are pleased to welcome Sonia Quaratino, our new Chief Medical Officer, who will cover updates on lacutamab and monalizumab. We'll then hand the call over to Yannis Morel, EVP of BD and Product Portfolio Strategy, who will then discuss our ANKET and ADC platform updates. We also have Frederic Lombard, our CFO, on the line for Q&A.
Mondher, I'll now hand the call over to you.
Mondher Mahjoubi
Thank you, Henry. Good morning, good afternoon, everyone, and thank you for joining us on this call.
Please move to Slide 4. So it is a reminder of our strategy. As an early clinical stage company, our business model centers around three key priorities where we look to drive value from our early R&D efforts through later-stage partnerships where it makes sense to do so.
Our ambition is to develop innovative drug candidates that contribute to transform cancer care through a strong pipeline of differentiated antibodies. Firstly, we look to create near-term value driven by our lead proprietary drug candidate, lacutamab, which is in clinical development for T-cell lymphoma with updates coming at this ASH meeting, including final CTCL and early PTCL data.